CATX at a glance
Perspective Therapeutics, Inc. (CATX, SEC CIK 728387) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Perspective Therapeutics, Inc. (CATX) shares worth $102.3 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Williamson Robert F III on November 18, 2026 of 15,000 shares at $0.80 per share.
- In the last 90 days, CATX insiders reported 10 open-market purchases ($175K) and 7 open-market sales ($1.6M) on Form 4, a net sale of $1.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 10 buys · 7 sells
- Net −$1.4M
- 13F holders
- 21 funds
- $102.3M · −3 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Grant revenue $0.2 million lower YoY; operating loss $34.3 million vs $27.9 million
- R&D expenses $26.1 million, up $5.8 million YoY, driven by clinical and manufacturing investment
- VMT-α-NET strongest program: Cohort 3 disease control 95%, versus Cohort 2 at 89%
- Cash, equivalents and short-term investments $201.7 million; operating cash use $83.5 million through nine months
- Expenses expected to rise; funding sufficient into 2028, with additional capital likely required before profitability
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- Carried-forward risk: unidentified or presently unknown risks could materially adversely affect business
- Market risk: securities price could decline significantly or permanently
- General business risk: identified risks could materially adversely affect financial condition and results of operations
AI summary of the CATX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Q3 2026 results for quarter ended September 30, 2026
- Recent business highlights accompany financial results, with details in Exhibit 99.1
Item 8.01: Other Events
- Updated corporate presentation posted November 9, 2026, providing investors with the company’s latest strategic and business overview
- Presentation filed as Exhibit 99.2, requiring review for updated pipeline, clinical, financing, or corporate developments
Item EX-99.2: Item EX-99.2
- Investor presentation outlines three independent clinical-stage radiopharmaceutical programs, each targeting data in 2027
- Pipeline targets neuroendocrine tumors, melanoma, advanced solid tumors and selected medullary thyroid cancers
Item EX-99.1: Item EX-99.1
- 3Q 2026 results: net loss $32.4M, or $0.27 per share, versus $26.0M and $0.35 in 3Q 2025
- Cash, equivalents and short-term investments $202M at September 30, 2026, funding planned milestones and investments into 2028
Item 8.01: Other Events
- New Phase 1/2a VMT-α-NET data and analyses presented at NANETS 2026
- Program targets unresectable or metastatic SSTR2-expressing neuroendocrine tumors
Item EX-99.1: Item EX-99.1
- Bamzireotide showed 75% 18-month PFS and 95% disease control across 57 SSTR2-positive GEP-NET patients
- Objective response rate reached 39% in the 57-patient enrichment subgroup, supporting potential registration-study patient selection
Item 8.01: Other Events
- Updated interim Phase 1/2a results for VMT01 melanoma diagnosis and treatment presented at SITC’s 41st Annual Meeting
- Trial targets unresectable or metastatic melanoma patients with melanocortin 1 receptor tumor expression
Item EX-99.2: Item EX-99.2
- Phase I/IIa monotherapy data support continued development of [212Pb]VMT01 in previously treated metastatic melanoma
- No dose-limiting toxicities among 20 patients, with grade ≥3 and serious TEAEs each affecting 5 participants (25%)
Item EX-99.1: Item EX-99.1
- Phase 1/2a VMT01 melanoma data: 75% disease control at the 3.0 mCi focus dose
- Two of eight patients achieved partial responses, with one ongoing approximately 40 weeks after first treatment
AI summaries of CATX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CATX
Don't miss the next CATX filing
- Alerts as it files. A push when CATX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CATX, by share count.
- Ask anything. An AI agent that reads every CATX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Williamson Robert F III | Buy | Nov 18, 2026 | 15,000 | $0.80 |
| Williamson Robert F III | Buy | Nov 17, 2026 | 25,000 | $0.84 |
| Morich Frank | Buy | Nov 16, 2026 | 15,000 | $0.94 |
| Woods Lori A | Buy | Nov 12, 2026 | 23,750 | $0.84 |
| Morich Frank | Buy | Nov 12, 2026 | 15,000 | $1.00 |
| Williamson Robert F III | Buy | Nov 12, 2026 | 6,289 | $0.84 |
| Williamson Robert F III | Buy | Nov 12, 2026 | 18,609 | $0.84 |
| Puhlmann Markus | Buy | Nov 12, 2026 | 35,000 | $0.84 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Gross Profit | $1.4M | - | - |
| Operating Income | - | -$90.9M | -$113.6M |
| Net Income | -$46.5M | -$79.3M | -$103.1M |
| Balance Sheet | |||
| Total Assets | $97.9M | $341.1M | $267.0M |
| Equity | $75.2M | $290.7M | $207.0M |
| ROE | -61.9% | -27.3% | -49.8% |
| Per Share | |||
| EPS | - | $-1.23 | $-1.40 |
| Cash Flow | |||
| Operating CF | -$36.9M | -$18.3M | -$82.5M |
| CapEx | $1.1M | $54.4M | $12.7M |
Source: XBRL data in Perspective Therapeutics, Inc. (CATX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CATX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 21 | $102.3M |
| Q2 2026 | 24 | $131.9M |
| Q1 2026 | 23 | $119.9M |
| Q4 2025 | 21 | $51.7M |
| Q3 2025 | 19 | $95.1M |
| Q2 2025 | 20 | $92.5M |
| Q1 2025 | 17 | $40.3M |
| Q4 2024 | 14 | $55.2M |
- BlackRock+2.33M (+25%)
- Two Sigma Investments+1.44M (+92%)
- Millennium Management+1.28M (+26%)
- Citadel Advisors LLC+173.2K (+5%)
- Renaissance Technologies LLC+162.5K (+275%)
- State Street Corp−4.02M (-67%)
- Morgan Stanley−1.29M (-67%)
- Goldman Sachs Group−996.4K (-57%)
- Citigroup−120.1K (-36%)
- Vanguard Portfolio Management LLC−101.3K (-9%)
- FMR LLC (Fidelity)−327.3K
- AQR Capital Management−28.0K
- Equitable Holdings Inc−10.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 159 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CATX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 8-K | Oct 23, 2026 | - | Analysis | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CATX SEC filings: frequently asked questions
Are CATX insiders buying or selling?
In the last 90 days, Perspective Therapeutics, Inc. (CATX) officers, directors and 10% owners reported 10 open-market purchases worth $175,386 by 5 insiders and 7 open-market sales worth $1.6 million by 2 insiders on Form 4, a net sale of $1.4 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CATX stock?
As of September 30, 2026, the largest Perspective Therapeutics, Inc. (CATX) holders among the 13F filers tracked by SignalX were BlackRock ($32.5 million), Millennium Management ($17.0 million), Vanguard Capital Management LLC ($12.1 million), Citadel Advisors LLC ($10.9 million), Two Sigma Investments ($8.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did CATX report in its latest 8-K?
Perspective Therapeutics, Inc. (CATX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Press release covers Q3 2026 results for quarter ended September 30, 2026.
What are the latest CATX SEC filings?
Perspective Therapeutics, Inc. (CATX) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 19, 2026.
What is CATX's SEC CIK number?
Perspective Therapeutics, Inc. (CATX)'s SEC Central Index Key (CIK) is 728387. EDGAR lists every CATX filing under that number.
Ask anything about CATX
The research agent reads CATX's filings, financials, insider trades and 13F holders, then answers with sources.